About Us
What Define Us
Who Are We?
Fibronostics is a global diagnostics company, shaping the future of noninvasive diagnostics with advanced solutions for screening, identification and monitoring of major metabolic diseases, effecting large patient populations globally.
We are a global company founded in Singapore, with labs and operations in the US.
Our Mission
Advancing Healthcare Globally with Noninvasive Solutions for the Detection of Metabolic Diseases
Our Scientific Advisors
Dr. Scott Friedman
Professor of Medicine and Chief, Liver Diseases Mount Sinai, New York
Dr. Meena Bansal
Professor of Medicine, Liver
Diseases Mount Sinai,
New York
Dr. Naim Alkhouri
VP of Academic Affairs, Chief of Transplant Hepatology,Arizona Liver Health, Phoenix, AZ
Our Management Team
Sven Henrichwark
President & Chairman
Brock Smith
Chief Executive Officer
Cassie Davies
Chief Financial Officer
John Lee
Chief Technology Officer
Shiva Kannan
Chief Operations Officer
Dr Ronald Quiambao
Chief Medical Officer MD
Dr Mona Munteanu
Chief Scientific Officer MD, PhD
Hear Directly from the Experts
Using Our Screening Tools
LIVERFASt™ is the premier choice when it comes to noninvasive Liver Screening solutions.
Here are some testimonials from the leading opinions in the industry
Dr. Naim Alkhouri
VP of Academic Affairs, Chief of Transplant Hepatology,Arizona
Liver Health, Phoenix, AZ
“MASH accounts for about 20-25% of all MASLD patients and can be challenging to diagnose… LIVERFASt™, uniquely gives us an opportunity to identify these patients and direct them to appropriate care that may help prevent progression of their disease.”
-Dr. Alkhouri, 2024
“LIVERFASt™ is a very reliable test that facilitates my care of MASH patients”
-Dr. Ankoma-Sey, 2024
Dr. Victor Ankoma-Sey
Director of Liver Transplant Program at Houston Methodist Transplant Center and Director of Liver Associates of Texas
Houston, TX
Dr. Parvez Mantry
Executive Medical Director Scientific Affairs, Innovation and New Technology, Methodist Health System, Plano, TX
“In my opinion the science and subsequent validation of the LIVERFASt™ test, fulfills a strong and unmet need for accurate diagnosis and monitoring of MASH .”
-Dr. Mantry, 2024
